Supplementary Appendix: Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial

Supplementary materials for the BE BRIGHT 4-Year Efficacy and Safety manuscript, including Plain Language Summary and supplementary methods, tables, and figures.

BE BRIGHT四年疗效与安全性研究手稿的补充材料，涵盖通俗语言摘要、补充方法、表格及图表。